In spite of recent development in the treatment armamentarium for multiple myeloma, overall survival (OS) still depends on risk status and sensitivity to treatment of each patient. We have evaluated the clinical relevance of the Revised International Staging System (R-ISS) by comparing it with the original ISS in 718 Japanese patients. The distribution of patients according to response was similar between the ISS and R-ISS stages. Treatment response was greatly influenced by initial treatment modalities and deeper response was observed more frequently in transplanted patients. The R-ISS discriminated the difference in OS between the stages more distinctly than the ISS (p = 9.0 × 10−15 and p = 4.0 × 10−10, respectively). Differences in OS were clarified by both R-ISS and ISS in non-transplanted patients (p = 2.4 × 10−12 and p = 1.4 × 10−8, respectively), but the ISS failed to distinguish the difference between the stages in transplanted patients (p = 0.13). In contrast, the R-ISS could at least discriminate the excellent prognosis of stage I patients whereas the distinction between stage II and III was not that clear (p = 0.033). The R-ISS stage II encompassed a large number of patients, and the prognosis was heterogeneous depending on the fulfillment of prognostic factors such as LDH and adverse cytogenetics. These results suggest that treatment factors and prognostic factors greatly affect the therapeutic response and outcome, and the R-ISS is superior to ISS in prognostication of both transplant-eligible and -ineligible patients in our current clinical practice.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121(5):749–757
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, Miguel JFS (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548
Anderson KC (2016) Progress and paradigms in multiple myeloma. Clin Cancer Res 22(22):5419–5427
Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 31(9):1915–1921
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420
Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J et al (2013) Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an international myeloma working group collaborative project. Leukemia 27(3):711–717
Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY (2014) Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol 32(20):2173–2180
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869
Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ (2016) Revised international staging system applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk 16(9):511–518
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA (2017) Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Haematologica 102(3):593–599
Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS, Jo JC, Kang HJ, Mun YC, Lee WS, Lee JJ, Suh C, Kim K, and the Korean Multiple Myeloma Working Party (2017) Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol 92(12):1280–1286
Shimizu K, Nagura E, Takatsuki K (2004) Management of patients with multiple myeloma in Japan: data of 1,383 patients from 16 hospitals and 1 treatment group. Leuk Lymphoma 45(12):2465–2469
Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K (2015) Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5:e349
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842–854
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473
Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458
Lahuerta JJ, Paiva B, Vidriales MB, Cordon L, Cedena MT, Puig N et al (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol 35(25):2900–2910
Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM (2017) Association of Minimal Residual Disease with Superior Survival Outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol 3(1):28–35
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346
Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K (2015) Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci 106(2):179–185
Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25(1):195–200
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study (2017) Lenalidomide, Bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311–1320
Cavo M, Hájek R, Pantani L, Beksac M, Oliva S, Dozza L, Johnsen HE, Petrucci MT, Mellqvist U-H, Conticello C, Driessen C, Marzocchi G, Dimopoulos MA, Zweegman S, Wu KL, Gamberi B, Crippa C, van der Holt B, Offidani M, Wester R, Vincelli ID, Troia R, Cornelisse P, Boccadoro M, Sonneveld P (2017) Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02/HO95 study. Blood 130(Suppl 1):397
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NWCJ, Einsele H, Blade J, Durie BGM, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood 127(24):2955–2962
Jung SH, Kim K, Kim JS, Kim SJ, Cheong JW, Kim SJ, Ahn JS, Ahn SY, Yang DH, Kim HJ, Lee JJ (2018) A prognostic scoring system for patients with multiple myeloma classified as stage II with the revised international staging system. Br J Haematol 181(5):707–710
Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce KE, Ketterling RP et al (2018) Evaluation of revised international staging system (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol 97(8):1453–1462
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G (2019) A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33(1):159–170
The following Japanese Society of Myeloma (JSM) institutions and investigators participated in this study: Tadao Ishida, Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo; Takahiro Kobayashi, Takaya Yamashita, Naoto Takahashi, Department of Hematology, Nephrology and Rheumatology, Akita University Hospital, Akita; Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, Department of Hematology, Gunma University Hospital, Maebashi; Atsushi Isoda, Morio Matsumoto, Morio Sawamura, Department of Hematology, National Hospital Organization Nishigunma National Hospital, Shibukawa; Eishi Nogiwa, Department of Internal Medicine, Usui Hospital, Yasunaka: Chiaki Nakaseko, Department of Hematology, Chiba University Hospital, Chiba; Fumihiko Nakamura, Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo; Go Yamamoto, Department of Hematology, Toranomon Hospital, Tokyo; Kenshi Suzuki, Department of Hematology, Japanese Red Cross Medical Center, Tokyo; Shotaro Hagiwara, Division of Hematology, Department of Internal Medicine, National Medical Center for Global Health and Medicine, Tokyo; Naoki Takezako, Department of Hematology, National Hospital Organization National Disaster Medical Center, Tokyo; Masao Hagihara, Department of Hematology, Eiju General Hospital, Tokyo; Shinya Okuda, Department of Hematology and Oncology, JR Tokyo General Hospital, Tokyo; Naoto Tomita, Department of Internal Medicine and Clinical Immunology, Yokohama City University Hospital, Yokohama; Tomonori Nakazato, Department of Hematology, Yokohama Municipal Citizen’s Hospital, Yokohama; Akiko Negoro, Department of Hematology, Japan Labor Health and Welfare Organization Yokohama Rosai Hospital, Yokohama; Takaaki Chou, Department of Medicine, Niigata Cancer Center Hospital, Niigata; Junji Ito, Department of Clinical Laboratory, Nagoya City Midori General Hospital; Nagoya; Hiroshi Kosugi, Department of Hematology, Ogaki Municipal Hospital, Ogaki; Hiroyuki Takamatsu, Department of Hematology, Kanazawa University Graduate School of Medical Science, Kanazawa; Hiroyuki Takamatsu, Department of Hematology, NTT WEST Kanazawa Hospital, Kanazawa; Tatsuharu Ohno, Division of Hematology and Immunology, Department of Internal Medicine, Ohtsu Red Cross Hospital, Ohtsu; Junya Kuroda, Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto; Chihiro Shimazaki, Department of Hematology, Japan Community Healthcare Organization Kyoto-Kuramaguchi Medical Center, Kyoto; Nobumasa Inoue, Department of Internal Medicine, National Hospital Organization Osaka Medical Center, Osaka; Toru Murayama, Department of Hematology, Hyogo Cancer Center, Akashi; Jun Konishi, Kazutaka Sunami, Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama; Yoshiaki Kuroda, Department of Hematology, Hiroshima University Hospital, Hiroshima; Mitsuhiro Itagaki, Hideki Asaoku, Department of Hematology, Hiroshima Red Cross Hospital, Hiroshima; Takaaki Miyake, Department of Hematology, Shimane University Hospital, Izumo; Toshio Wakayama, Department of Hematology, Shimane Prefectural Central Hospital, Izumo; Takeshi Harada, Masahiro Abe, Department of Hematology, Tokushima University Hospital, Tokushima; Shuji Ozaki, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima; Toshihiro Hashimoto, Department of Internal Medicine, Tokushima Municipal Hospital, Tokushima; Yasushi Takamatsu, Division of Medical Oncology, Hematology, and Infectious Disease, Department of Internal Medicine, Fukuoka University, Fukuoka; Naokuni Uike, Department of Hematology, National Kyushu Cancer Center, Fukuoka; Hiroyuki Hata, Department of Immunology and Hematology, Faculty of Life Sciences, Graduate School of Health Sciences, Kumamoto University, Kumamoto; Naoko Harada, Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Conflict of interest
Dr. Kazutaka Sunami has received research funding from Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharmaceutical Co. Ltd., and Celgene Co. Ltd. All other authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ozaki, S., Handa, H., Saitoh, T. et al. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol 98, 1703–1711 (2019). https://doi.org/10.1007/s00277-019-03702-1
- Multiple myeloma
- International Staging System
- Revised International Staging System
- Novel agents
- Autologous stem cell transplantation